◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 2576

Zhejiang Taimei Medical Technology Co., Ltd. (2576) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Health Information Services · DATA UPDATED 2026-08-10

Zhejiang Taimei Medical Technology Co., Ltd. (2576) operates in the Health Information Services industry and is headquartered in Jiaxing, China with about 681 employees. Its market capitalization is roughly CNY 3 billion. In the fiscal year ended 2025-12-31, 2576 reported CNY 512M in revenue and (CNY 43M) in net income.

Zhejiang Taimei Medical Technology Co., Ltd. provides digital solutions for life sciences research, development, and commercialization in Mainland China and internationally.

Interactive charts & full statements →

2576 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 512MCNY 551MCNY 573MCNY 549M
Gross ProfitCNY 218MCNY 225MCNY 179MCNY 185M
Operating Income (EBIT)(CNY 51M)(CNY 254M)(CNY 390M)(CNY 476M)
Net Income(CNY 43M)(CNY 215M)(CNY 347M)(CNY 413M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2576 Free Cash Flow History

2576 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 1.6BCNY 1.6BCNY 1.4BCNY 1.8B
Total LiabilitiesCNY 366MCNY 349MCNY 403MCNY 442M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2576 viewer.

Other Companies in Health Information Services

← 2575All “0-9” companies2577 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.